Experts say dangerous sleep apnoea affects an estimated 8 million in the UK alone, and everything from evolution to obesity or even the climate crisis could be to blame ...

REMSleep says the final pieces of its commercial strategy for the DeltaWave nasal pillow system are falling into place as the company prepares for a broader market push.

It’s estimated eight million people in the UK have sleep apnoea, which causes breathing to repeatedly stop and start ...

ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre screening, widening its reach before patients ever enter a sleep lab. Recent FDA approvals are supporting ResMed's role ...

Air Voel, a fast-growing Canadian provider of sleep therapy and respiratory care equipment, has announced the expansion ...

This one is for investors seeking quality, global reach, and durable earnings. The post 3 reasons to buy this heavyweight ASX ...

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...

Resmed Inc () has held its Q2 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools ...

Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

Resmed shares are down a bit today, even though second-quarter results came in ahead of the consensus forecast.

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP ...

Medical device company ResMed (NYSE:RMD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit of $2.81 per share ...